Marinus Pharmaceuticals to Provide Business Update and Announce First Quarter 2021 Financial Results on May 13, 2021

Rhea-AI Summary

Marinus Pharmaceuticals (Nasdaq: MRNS) will release its Q1 2021 financial results on May 13, 2021, after the market closes. A conference call is scheduled for the same day at 4:30 PM ET to discuss the results and provide a business update. The company is focused on developing innovative therapeutics for rare seizure disorders, including Ganaxolone, which targets GABA_A receptors. Marinus recently completed a pivotal Phase 3 trial in children with CDKL5 deficiency and is actively pursuing trials in refractory status epilepticus.

Positive

• Completed the first Phase 3 pivotal trial in children with CDKL5 deficiency disorder.
• Conducting a Phase 2 trial in tuberous sclerosis complex.
• Initiated a Phase 3 trial in refractory status epilepticus.

Negative

• None.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it plans to release financial results for the first quarter ended March 31, 2021 after the market close on May 13, 2021. The company will host a conference call at 4:30 pm Eastern Time on May 13, 2021 to provide a business update and discuss the financial results.

Thursday, May 13: 4:30 PM Eastern Time

Domestic: (833) 979-2765
International: (343) 761-2590
Webcast Link: https://event.on24.com/wcc/r/3081130/88D98EC340CEF9104A24FACA2A4283B7
Conference ID: 6864408

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABA_A receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 2 trial in tuberous sclerosis complex, and has recently disclosed top line results from its Phase 2 proof-of-concept trial in PCDH19-related epilepsy. The company has initiated a Phase 3 trial in refractory status epilepticus. For more information visit www.marinuspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210507005315/en/

FAQ

When will Marinus Pharmaceuticals release its Q1 2021 financial results?

Marinus Pharmaceuticals will release its Q1 2021 financial results on May 13, 2021, after market close.

What is the purpose of the conference call on May 13, 2021?

The conference call on May 13, 2021, at 4:30 PM ET will provide a business update and discuss the financial results.

What are the key developments involving Ganaxolone by Marinus Pharmaceuticals?

Ganaxolone is undergoing trials as a treatment for rare seizure disorders, with recent successful Phase 3 and ongoing Phase 2 trials.

What trials is Marinus Pharmaceuticals currently conducting?

Marinus is conducting a Phase 2 trial in tuberous sclerosis complex and a Phase 3 trial in refractory status epilepticus.